The pharmaceutical industry faces a perfect storm, with unsustainable growth in healthcare costs, increasing costs of drug discovery, and the shift to a value-based payment model.
The benefits of adherent patients are no secret: better outcomes, a more stable treatment pathway and of course better revenues for pharma are all possible.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.